Screener
Myriad Genetics MYGN Long-Term Debt
Long-Term Debt at other companies
Other financials
Where this comes from
Reported directly by Myriad Genetics in its filing.
Tagged under the XBRL concept us-gaap:LongTermDebtNoncurrent.
The source filing: Myriad Genetics’s 10-Q, filed May 6, 2026.
- Filed
- May 6, 2026, 6:05 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0000899923-26-000038
| Line item | March 31,2026 | December 31,2025 |
|---|---|---|
| Accrued liabilities | 90.5 | 96.9 |
| Current maturities of operating lease liabilities | 7.1 | 6.9 |
| Total current liabilities | 130.2 | 133.8 |
| Long-term debt | 120.3 | 119.9 |
| Noncurrent operating lease liabilities | 84.1 | 83.0 |
| Other long-term liabilities | 1.7 | 1.9 |
| Total liabilities | 336.3 | 338.6 |
| Commitments and contingencies |
Item 1. Financial Statements.
FAQ
- What is Myriad Genetics's long-term debt?
- Myriad Genetics (MYGN) reported long-term debt of $120.3M in Q1 2026.
- How has Myriad Genetics's long-term debt changed year-over-year?
- Myriad Genetics's long-term debt increased by 102.9% year-over-year, from $59.3M to $120.3M.
- What is the long-term trend for Myriad Genetics's long-term debt?
- Over 5 years (2020 to 2025), Myriad Genetics's long-term debt has grown at a -11.8% compound annual growth rate (CAGR), from $224.8M to $119.9M.
- What does long-term debt mean?
- Bonds, term loans, notes payable, and other borrowings with maturities beyond one year — the primary long-term financing source.
Ask your AI about Myriad Genetics's long-term debt.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude